Opportunity Cost for Early Treatment of Chagas Disease in Mexico

PLoS Neglected Tropical Diseases

Volumn 8, Issue 4, 2014, Pages

  Ramsey, Janine M ^a   Elizondo Cano, Miguel ^b   Sanchez González, Gilberto ^b   Peña Nieves, Adriana ^c   Figueroa Lara, Alejandro ^d  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c Medicina y Agricultura   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHAGAS DISEASE; COST; COUNSELING; DECISION MAKING; DISEASE COURSE; DRUG COST; EVIDENCE BASED PRACTICE; HOSPITALIZATION COST; LABORATORY TEST; MEXICO; PARAMETERS; POLICY; PUBLIC HEALTH; QUALITY OF LIFE; SIMULATION; TROPICAL DISEASE;

ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; COHORT STUDIES; EARLY DIAGNOSIS; HEALTH CARE COSTS; HUMANS; MEXICO; SECONDARY PREVENTION;

EID: 84901278904     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002776     Document Type: Article

References (47)

1. Diaz J, (2008) Recognizing and reducing the risks of Chagas disease (American trypanosomiasis) in travelers. J Travel Med 15: 184-195.
2. Prata A, (2001) Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100.
3. World Health Organization (2012) Chagas disease (American trypanosomiasis) fact sheet N° 340, august 2012. Available:http://www.who.int/mediacentre/factsheets/fs340/en/index.html. Accessed 10 October 2012.
4. Coura JR, Viñas PA, (2010) Chagas disease: a new worldwide challenge. Nature 465: s6-s7.
5. Ramsey JM, Cruz A, Salgado L, Espinosa L, Ordoñez R, et al. (2003) Efficacy of pyrethroid insecticides against domestic and peridomestic populations of Triatoma pallidipennis and Triatoma barberi (Reduviidae:Triatominae) vectors of Chagas' disease in Mexico. J Med Entomol 40: 912-920.
6. Ibarra-Cerdeña CN, Sánchez-Cordero V, Townsend Peterson A, Ramsey JM, (2009) Ecology of North American Triatominae. Acta Trop 110: 178-186.
7. Novelo-Garza BA, Benítez-Arvizu G, Penña-Benítez A, Galván-Cervantes J, Morales-Rojas A, (2010) Detección de Trypanosoma cruzi en donadores de sangre. Rev Med Inst Mex Seguro Soc 48: 139-144.
8. Segura E, Escobar-Mesa A, (2005) Epidemiología de la enfermedad de Chagas en el estado de Veracruz. Salud Publica Mex 47: 201-208.
9. López T, Panzera F, Tun E, Ferrandis I, Ramsey J, (2009) Contribuciones de la genética y la proteómica al estudio de la enfermedad de Chagas. Salud Publica Mex 51: S410-S423.
10. Velasco O, Valdespino J, Tapia R, Salvatierra B, Guzmán C, et al. (1992) Seroepidemiología de la Enfermedad de Chagas en México. Salud Publica Mex 34: 186-196.
11. Guzmán C, García L, Florián J, Guerrero S, Torres M, et al. (1998) Riesgo de transmisión de Trypanosoma cruzi por transfusión de sangre en México. Rev Panam Salud Publica 4: 94-99.
12. Drummond M, O'brien B, Stooddart G, Torrance G (2001) Métodos para la evaluación económica de los programas de asistencia sanitaria. Madrid: Ediciones Díaz de Santos.367 p.
13. Castillo M (2007) Dimensión de costos de la Enfermedad de Chagas. In: Rosas F, Vanegas D, Cabrales M. Enfermedad de Chagas. Bogotá, DC: Sociedad Colombiana de cardiología y cirugía cardiovascular. pp. 205-215.
14. Rosas F, Guhl F, Luquetti A (2007) Tratamiento etiológico de la Enfermedad de Chagas. In: Rosas F, Vanegas D, Cabrales M. Enfermedad de Chagas. Bogotá, DC: Sociedad Colombiana de cardiología y cirugía cardiovascular. pp. 139-143.
15. World Health Organization (2010) Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical disease. France: World Health Organization.172p.
16. Vallejo M, Montenegro P, Reyes PA, (2002) How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital. Arch Cardiol Mex 72: 129-37.
17. Pérez-Cuevas R, Doubova SV, Suarez-Ortega M, Law M, Pande AH, et al. (2012) Evaluating quality of care for patients with type 2 diabetes using electronic health record information in Mexico. BMC Med Inform Decis Mak 12: 50.
18. Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR, (2010) The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis 4: e916.
19. Wilson LS, Strosberg AM, Barrio K, (2005) Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models. Am J Trop Med Hyg 73: 901-910.
20. Machado-de-Assis GF, Diniz GA, Montoya RA, Dias JC, Coura JR, et al. (2013) A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention. Mem Inst Oswaldo Cruz 108: 873-880.
21. Rodriques-Coura J, de Castro SL, (2002) A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
22. Sonnenberg FA, Beck JR, (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13: 322-338.
23. Secretaría de Salud de México (2012) Encuesta Nacional de Salud y Nutrición 2012. Available: http://ensanut.insp.mx/basesdoctos.php#.Umb8lvkz2QM. Accesed 8 August 2013.
24. Secretaría de Gobernación (2011) Diario Oficial de la Federación, martes 14 de junio 2011. Available: http://dof.gob.mx/nota_detalle.php?codigo=5296312&fecha=18/04/2013. Accesed 10 January 2013.
25. Instituto Mexicano del Seguro Social (2013) Salario promedio diario. Available: http://www.stps.gob.mx/bp/secciones/conoce/areas_atencion/areas_atencion/web/menu_infsector.html. Accessed 10 January 2013.
26. International Monetary Fund (2009) International exchange rates. Washington, DC: IMF.
27. US Bureau of Labor Statistics (2009) Consumer price index: historical dataset. Washington, DC: Bureau of Labor Statistics.
28. Castillo-Riquelme M, Guhl F, Turriago B, Pinto N, Rosas F, et al. (2008) The costs of preventing and treating Chagas disease in Colombia. PLoS Negl Trop Dis 2: e336.
29. Basombrío MA, Schofield CJ, Rojas CL, del Rey EC, (1998) A cost-benefit analysis of Chagas disease control in north-western Argentina. Trans R Soc Trop Med Hyg 92: 137-143.
30. Schenone H, (1998) Human infection by Trypanosoma cruzi in Chile: epidemiology estimates and costs of care and treatment of the chagasic patient. Bol Chil Parasitol 53: 23-26.
31. Akhavan D (1996) Cost-effectiveness analysis of the Chagas disease control programme in Brazil. Project BRA-093/15 with technical Assistance from UN: Brasilia. 37 p.
32. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ, (2013) Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis 13: 342-348.
33. Manne JM, Snively CS, Ramsey JM, Salgado MO, Bärnighausen T, et al. (2013) Barriers to Treatment access for Chagas Disease in Mexico. PLos Negl Trop Dis 7: e2488.
34. Dumonteil E, (1999) Update on Chagas's disease in Mexico. Salud Pública Mex 41: 322-327.
35. Consejo Nacional de Población (2012). Tasa de mortalidad general. Available: http://www.conapo.gob.mx/en/CONAPO. Accessed 10 January 2013.
36. Moreno E, Valerio-Campos I, Goyenaga-Castro P, (2007) Miocarditis y miocardiopatía dilatada por Trypanosoma cruzi: Reporte de un caso. Parasitol Latinoam 62: 148-153.
37. Abad-Franch F, Santos WS, Schofield CJ, (2010) Research needs for Chagas disease prevention. Acta Trop 115: 44-54.
38. Shikanai-Yasuda MA, Lopes MH, Tolezano JE, Umezawa E, Amato-Neto V, et al. (1990) Acute Chagas' disease: transmission routes, clinical aspects and response to specific therapy in diagnosed cases in an urban center. Rev Inst Med Trop Sao Paulo 32: 16-27.
39. Rassi A Jr, Rassi A, Marin-Neto JA, (2010) Chagas disease. Lancet 375: 1388-1402.
40. Grupo Jasem (2013) Lista de precios. Available at: http://grupojasem.com/sistema/ca/ListasdePrecios/REPRESA/data/BIORAD%202013.pdf. Accessed 8 February 2013.
41. Viotti R, Vigliano C, Armenti H, Segura E, (1994) Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-162.
42. Bellini MF, Silistino-Souza R, Varella-Garcia M, de Azeredo-Oliveira MT, Silva AE, (2012) Biologic and genetics aspects of Chagas disease at endemic Areas. J Trop Med 357948: 1-11.
43. Fabbro DL, Streiger ML, Arias ED, Bizai ML, Del Barco M, et al. (2007) Trypanocide treatment among adults with chronic Chagas disease living Santa Fe City (Argentina), over mean follow -up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40: 1-10.
44. Teixeira AR, Hecht MM, Guimaro MC, Sousa A, Nitz N, (2011) Pathogenesis of Chagas' disease: parasite persistence and autoimmunity. Clin Microbiol Rev 24: 592-630.
45. Organización Panamericana de la Salud (2008) Programa regional para el control de la enfermedad de Chagas en América Latina. Iniciativa de bienes públicos regionales. Washington: OPS. 242 p.
46. Viotti R, Vigliano C, Lococo B, Petti M, Bertocchi G, et al. (2005) Clinical predictors of chronic chagasic myocarditis progression. Rev Esp Cardiol 58: 1037-1044.
47. Instituto Mexicano del Seguro Social (2011) Grupos Relacionados con el Diagnóstico. México: IMSS. 230 p.